BalanzGM is reader-supported. Some links on this page are affiliate links — if you buy through them we may earn a commission at no extra cost to you. It never changes what the evidence section says. See our affiliate disclosure.
This article summarizes published evidence — FDA-approved drug labeling, an FDA approval letter, a randomized controlled trial, and two peer-reviewed reviews, each cited below. It is written by journalists, not clinicians, and has not been reviewed by a physician. Talk to a doctor or a board-certified dermatologist before starting or stopping any treatment. Full medical disclaimer.
This page covers medicines that carry pregnancy warnings. If you are pregnant, breastfeeding, or may become pregnant, the sections below are a reason to speak to a clinician before starting anything, not a reason to self-select a treatment.
What the status labels on this page mean
- FDA-approved
- The FDA reviewed the evidence and approved this drug for pattern hair loss.
- Off-label
- An FDA-approved drug being prescribed for something other than what it was approved for. Legal and common, but the hair loss use has not been through FDA review.
- Compounded
- Mixed to order by a pharmacy. Not FDA-approved, and not reviewed by the FDA for safety, effectiveness or quality.
- FDA-cleared
- Allowed on the market through the 510(k) route because it is judged similar to a device already sold — not the same as the FDA independently approving its effectiveness.
- Supplement
- A dietary supplement. The FDA does not approve supplements before they go on sale, and claims about them are not FDA-evaluated.
What this page found
- One treatment is FDA-approved for female pattern hair loss: topical minoxidil. The 5% aerosol for women was approved on 28 February 2014, over the counter, half a capful once daily.[2]
- Finasteride’s label states it is not indicated for use in women.[4] Its only randomized trial in postmenopausal women — 137 participants — found no significant difference against placebo at one year.[5]
- Finasteride is pregnancy category X. Women who may become pregnant must not handle crushed or broken tablets.[4][5]
- Oral minoxidil is prescribed off-label Off-label. In a 1,404-patient series where two thirds were women, unwanted body hair occurred in 15.1% and no severe adverse events were reported.[6] Spironolactone is also prescribed off-label, but we could not obtain its trial data — see below.
- Postpartum shedding is usually temporary and affects around 20% of women. It is a different condition from pattern hair loss and is usually treated with time, not drugs.[8]
- The 5% strength outperforms 2% on patient self-assessment — but with more itching, irritation and unwanted facial hair.[3]
Female pattern hair loss is not male pattern hair loss with different marketing
The two conditions look different on the scalp and they have different treatment evidence. Male pattern loss recedes at the temples and thins at the crown. Female pattern hair loss diffuses across the top of the scalp while the frontal hairline is usually preserved — which is why the Ludwig scale describes thinning bounded at the front by a line one to three centimeters behind the hairline, rather than a receding line.[10]
More importantly, the drug evidence does not transfer. A treatment that works in men is not thereby a treatment for women, and in at least one prominent case the trial in women came back negative. Any page that gives you the same recommendations in both directions has not read the trials.
The one FDA-approved option
Topical minoxidil FDA-approved is it. Women’s Rogaine 5% Topical Aerosol was approved under NDA 021812/S-009 on 28 February 2014 as an over-the-counter product, dosed at half a capful once daily.[2] The 2% solution had been approved earlier under NDA 019501. Nothing else in this article carries FDA approval for this condition.
What the label actually promises, in its own terms
Results may be seen at three months with once-daily use, and some women may need at least six months.[1]
If you stop, normal hair loss will start again and you are likely to lose the newly grown hair within three to four months.[1]
It warns the product is extremely flammable, is not for use under 18, may cause unwanted facial hair growth, and may be harmful if used during pregnancy or breastfeeding.[1]
Source: FDA-approved Drug Facts labeling[1].
What the trial found
Lucky AW, Piacquadio DJ, Ditre CM, et al. Journal of the American Academy of Dermatology, 2004
- Design
- Randomized, placebo-controlled trial, 48 weeks
- Participants
- 381 women aged 18-49 — 5% (n=153), 2% (n=154), placebo (n=74)
- Main result
- The 5% group was significantly superior to the 2% group on patient self-assessment at week 48.[3]
Stated limitation: Itching, local irritation and hypertrichosis were all more frequent in the 5% group. The published abstract does not give absolute hair counts per arm, so we cannot show you the underlying numbers.
Source: published randomized controlled trial[3].
Finasteride in women: what the trial found
This is the section most commercial hair loss pages skip, because the answer is inconvenient.
The FDA-approved label states: PROPECIA is not indicated for use in women.[4] That is not a cautious hedge. The indication section names men.
What the trial found
Price VH et al., 2000, as reported in Iamsumang et al., Drug Design, Development and Therapy, 2020
- Design
- Double-blind randomized controlled trial, 12 months
- Participants
- 137 postmenopausal women with mild to moderate female pattern hair loss
- Main result
- No significant difference in hair count between finasteride 1 mg and placebo after one year. Photographic assessment and scalp biopsy showed no improvement either.[5]
Stated limitation: This is the only randomized controlled trial of finasteride in this population. Studies in premenopausal women used higher doses of 1.25 to 5 mg per day with conflicting results: one open-label study found no response, while uncontrolled prospective studies reported 62% to 81% improvement — but those were confounded by concurrent oral contraceptives and antiandrogens.[5]
Source: peer-reviewed evidence review[5].
The review’s own conclusion is measured rather than dismissive: finasteride Off-label may be considered as an alternative option, preferentially in postmenopausal women to minimize the risk of teratogenicity.[5] That is a real position held by dermatologists. It is also a long way from the confident recommendation you will find on pages that sell it.
The pregnancy warning, stated plainly
Oral minoxidil and spironolactone: used, but off-label
Both are prescribed for female pattern hair loss. Neither is approved for it, so both carry the off-label badge wherever they appear on this site.
Low-dose oral minoxidil Off-label has the better documented safety record of the two. In the largest series — 1,404 patients, of whom 943 (67.2%) were women — hypertrichosis occurred in 15.1%, lightheadedness in 1.7%, fluid retention in 1.3%, and no severe adverse events were reported. Only 1.7% stopped treatment.[6] Typical dosing described in a 2025 review starts women at 0.5 or 0.625 mg daily, increasing every three months to a maximum of 2.5 mg — far below the 10 to 40 mg range the tablet is approved for in hypertension.[7]
Low-dose oral minoxidil: reported effects (n=1,404, two thirds women)
Off-label
We could not verify efficacy figures for spironolactone. A placebo-controlled randomized trial in premenopausal women has been published, but the full text sits behind a paywall our tooling could not pass, and a second 2024 paper was likewise inaccessible. Rather than repeat numbers we have not read in context, we will say only what is well established: spironolactone is used off-label for female pattern hair loss, and its published evidence base is dominated by retrospective and small pilot studies. Ask your prescriber for the specific evidence they are relying on.
Postpartum shedding is a different condition
If your hair started falling out in handfuls a few months after giving birth, that is very likely telogen effluvium, not female pattern hair loss, and the treatment is usually time.
| Source | What it says about timing |
|---|---|
| Rebora, Clin Cosmet Investig Dermatol, 2019[8] | Onset two to four months after delivery; usually lasts about two months, rarely longer; usually resolves completely. Affects around 20% of women. Chronic telogen effluvium is defined as lasting more than six months. |
| Johns Hopkins Medicine[9] | Usually begins around three months after birth and usually ends around six to twelve months after birth. High pregnancy estrogen prolongs the growth phase; after delivery hormones normalize and hairs enter the shedding phase together. |
We are giving you both because they frame the duration differently, and merging them into one tidy number would be inventing a consensus that the sources do not have. What they agree on is that it is temporary and tends to resolve without treatment. Johns Hopkins puts it directly: patience matters, because postpartum hair loss is usually temporary and tends to resolve on its own.[9]
Two practical caveats. If shedding persists beyond six months, that meets the published definition of chronic telogen effluvium and is worth investigating rather than waiting out.[8] And minoxidil’s label warns it may be harmful if used while pregnant or breastfeeding[1] — which is exactly the window postpartum shedding falls in.
Laser devices and supplements
Home-use low-level laser devices FDA-cleared are FDA-cleared, not FDA-approved — a different and weaker standard, covered in detail in our laser cap article. A meta-analysis of seven double-blind randomized trials covering 607 people found a standardized mean difference of 1.27 in hair density against sham devices, with effects reported in both men and women.[11] That is a real signal from real trials; it is not the same class of evidence as an approved drug.
Supplements Supplement such as Nutrafol are regulated as food, not medicine. They are not evaluated by the FDA for treating any condition, and the manufacturer’s own product page lists a botanical blend rather than an approved active ingredient.[13] At $792 a year prepaid, or up to $1,056 at list price, they are among the most expensive things in this article, and the only unapproved category being sold to you without a prescriber in the room.
What the options cost over twelve months
| Option | 12-month cost | Status |
|---|---|---|
| Topical minoxidil 5%, generic retail | Varies by retailer — check locally | FDA-approved |
| Ro topical minoxidil, 12-month plan | $156[12] | FDA-approved |
| Ro women’s oral minoxidil, quarterly plan | $360[12] — the men’s 12-month plan is $288; this is the women’s quarterly plan, which has no 12-month tier | Off-label |
| Ro Women’s Hair Solution Rx (minoxidil + tretinoin + melatonin) | $480[12] | Compounded |
| Nutrafol Women Advanced | $792 prepaid, up to $1,056 at list price[13] | Supplement |
The full cost picture, including the fees that never appear on a pricing page, is in what hair loss treatment actually costs per year.
A reasonable order of operations
| Step | Why it is in this order |
|---|---|
| Get the diagnosis first | Pattern hair loss, telogen effluvium, thyroid disease and iron deficiency all present as thinning hair and are managed completely differently. Treating the wrong one wastes a year. |
| Start with topical minoxidil 5% | It is the only FDA-approved option, it is available over the counter, and it is the cheapest thing on this page. |
| Give it six months before judging it | The approved label says some women need at least six months to see results.[1] |
| Only then discuss off-label options | Oral minoxidil and spironolactone are prescriber conversations that depend on your cardiovascular history and whether pregnancy is possible — not choices to make from a website. |
| Treat supplements as optional, not foundational | They are the most expensive unapproved category here, and they are not a substitute for the approved drug. |
The diagnosis is the part worth paying for
Almost everything in this article past the over-the-counter minoxidil requires a prescriber — and the single most valuable step is establishing which condition you actually have. Sesame Care is a US marketplace that lists consultation prices upfront in cash, including hair loss visits.
Sesame Care is a US telehealth marketplace that lists upfront cash prices for appointments. The link below is an affiliate link: if you book, we may earn a commission at no extra cost to you.
See hair loss consultation prices →Where to go next
Frequently asked questions
What is the only FDA-approved treatment for female pattern hair loss?
Topical minoxidil. The 5% topical aerosol for women was approved on 28 February 2014 as an over-the-counter product dosed at half a capful once daily, and 2% minoxidil solution was approved earlier. No other drug carries FDA approval for female pattern hair loss. Everything else you will be offered – oral minoxidil, spironolactone, finasteride, compounded topicals, supplements – is off-label, unapproved, or a supplement.
Can women take finasteride for hair loss?
The FDA-approved label states plainly that finasteride is not indicated for use in women. The only randomized controlled trial in postmenopausal women – 137 women with mild to moderate female pattern hair loss – found no significant difference in hair count against placebo after one year. Some prescribers use it off-label anyway, and a review of the evidence suggests it be considered preferentially in postmenopausal women specifically to minimize teratogenic risk, because finasteride is pregnancy category X.
Why can’t I handle a broken finasteride tablet if I might become pregnant?
Because finasteride can be absorbed through the skin, and animal studies show a dose-dependent risk of hypospadias in male offspring. The FDA label instructs that women who are or may become pregnant should not handle crushed or broken tablets. Intact coated tablets are stated to be safe to handle provided they are not broken.
How long does postpartum hair loss last?
Two sources give slightly different framings. A 2019 review describes postpartum telogen effluvium as starting two to four months after delivery, usually lasting about two months, rarely longer, and typically resolving completely, affecting around 20% of women. Johns Hopkins describes it as usually beginning around three months after birth and usually ending around six to twelve months after birth. Both agree it is temporary and tends to resolve on its own.
Does minoxidil cause facial hair in women?
It can. In the 381-woman randomized trial, hypertrichosis – unwanted hair growth – was more common in the 5% group than the 2% group, along with itching and local irritation. The FDA label for the women’s 5% product warns it may cause unwanted facial hair growth. Applying only the labeled dose to the scalp, washing your hands afterwards and letting the scalp dry reduces transfer.
Sources
- U.S. Food and Drug Administration. Women’s ROGAINE 5% Minoxidil Topical Aerosol, Drug Facts label. 2019. accessdata.fda.gov
- U.S. Food and Drug Administration. Approval letter, Women’s ROGAINE 5% Topical Aerosol, NDA 021812/S-009. 28 February 2014. accessdata.fda.gov
- Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-553. PMID 15034503.
- U.S. Food and Drug Administration. PROPECIA (finasteride) tablets, prescribing information. 2022. accessdata.fda.gov
- Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. 2020;14:951-959. dovepress.com
- Vañó-Galván S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. PMID 33639244.
- Jimenez-Cauhe J, Lo Sicco KI, Shapiro J, et al. Characterization and management of adverse events of low-dose oral minoxidil treatment for alopecia: a narrative review. J Clin Med. 2025;14(6):1805. mdpi.com
- Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol. 2019;12:583-590. dovepress.com
- Johns Hopkins Medicine. Postpartum hair loss. hopkinsmedicine.org
- Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97:247-254.
- Lueangarun S, et al. A systematic review and meta-analysis of randomized controlled trials of United States FDA-approved, home-use, low-level light/laser therapy devices for pattern hair loss. J Clin Aesthet Dermatol. 2021. jcadonline.com
- Ro. Pricing. ro.co (checked 8 September 2026)
- Nutrafol. Women’s Advanced product page. nutrafol.com (checked 8 September 2026)
Affiliate disclosure: this page contains affiliate links. We may earn a commission when you buy through them, at no additional cost to you. Commissions never determine what we cover or what the evidence sections say. Read our full affiliate disclosure.
How we researched this: every figure on this page is sourced to a numbered reference below. For this article those sources are FDA-approved drug labeling, an FDA approval letter, two randomized controlled trials, a 1,404-patient safety series, two peer-reviewed reviews, a meta-analysis, and each service’s own published pricing. Where a figure could not be verified from a primary source, we say so in the text rather than estimating. Prices were checked on the date shown at the top of this page and change frequently. We do not test products and we do not practice medicine. See our review methodology.
